Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review
Rattachement africain : it, gr, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Due to the involvement of biofilms in the pathogenesis of bone and joint infections (BJI), the treatment of these infections is often challenging, especially when multidrug- or extensively drug-resistant (MDR/XDR) pathogens are involved. Intravenous fosfomycin (FOS) is a phosphoenolpyruvate analogue with a unique mode of action and broad-spectrum activity against both Gram-positive (GP) and Gram-negative (GN) pathogens. It is used in various severe and deep-seated infections, including BJIs. This review article focuses on preclinical and clinical data surrounding the use of FOS for biofilm-related BJIs. Data from several in vitro and animal models of infection demonstrated that FOS, especially in combination with other antibiotics, is effective against biofilms of (methicillin-resistant) Staphylococcus spp., (vancomycin-resistant) Enterococcus spp., carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales, and MDR Pseudomonas aeruginosa. Data from clinical studies, mostly retrospective observational studies and case reports/case series, revealed that FOS was typically used in combination with other antibiotics for the treatment of various BJI, including acute and chronic osteomyelitis, prosthetic joint infections, and fracture-related infections, in adult and pediatric patients. Success rates often exceeded 80%. FOS exhibits good and fast penetration into bone tissue and is generally well tolerated, with only a few adverse drug reactions, such as gastrointestinal disorders and electrolyte imbalances. Collectively, the data indicate that FOS is a valuable option as part of combination regimens for the treatment of BJIs caused by both GP and GN bacteria.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review
- Date Crossref
- 23/04/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Azienda USL di Bologna pays non établi dans la noticeÉtablissement de santé
-
University of Bologna Department of Medical and Surgical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
National and Kapodistrian University of Athens Medical School pays non établi dans la noticeUniversité ou école supérieure
-
Laiko General Hospital of Athens pays non établi dans la noticeÉtablissement de santé
-
InfectoPharm (Germany) pays non établi dans la noticeEntreprise
-
Infectious Diseases Unit pays non établi dans la noticeInstitution
-
InfectoPharm Arzneimittel und Consilium GmbH pays non établi dans la noticeEntreprise
Azienda USL di Bologna, Department of Medical and Surgical Sciences — University of Bologna et Medical School — National and Kapodistrian University of Athens, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.